Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX

Table 5 Univariate and multivariate Cox regression analyses of prognostic factors for progression-free survival

	HR (95%CI)	P value	HR (95%CI)	P value
Sex
Male
Female	0.871 (0.268-2.830)	0.818
Age
≤ 60 years
> 60 years	0.696 (0.228-2.131)	0.526
Tumor differentiation
Poor
Moderate	0.267 (0.059-1.206)	0.086
Histological type
PC
Non-PC	0.653 (0.219-1.945)	0.444
Tumor location
Cardia
Gastric body	2.425 (0.489-12.034)	0.279
Gastric antrum	1.484 (0.288-7.650)	0.637
Lauren classification
Intestinal
Diffuse	6.284 (1.389-28.431)	0.017	5.545 (0.568-12.955)	0.011
cT
cT3
cT4	4.854 (1.074-21.936)	0.040
cN
cN0
cN1-3	1.951 (0.254-15.009)	0.521
pT
pT0-2
pT3-4	3.756 (1.030-13.688)	0.045
pT
pN0
pN1-3	3.333 (1.025-10.839)	0.045
Baseline CD3+ T lymphocytes (%)	1.008 (0.959-1.059)	0.753
Baseline CD4+ T lymphocytes (%)	0.990 (0.930-1.055)	0.764
Baseline CD8+ T lymphocytes (%)	1.017 (0.961-1.075)	0.561
Baseline NLR	1.035 (0.722-1.485)	0.852
Baseline PLR	1.002 (0.995-1.008)	0.622
Baseline MLR	0.679 (0.152-3.201)	0.642
Post-treatment CD3+ T lymphocytes (%)	0.977 (0.928-1.028)	0.373
Post-treatment CD4+ T lymphocytes (%)	1.003 (0.959-1.049)	0.894
Post-treatment CD8+ T lymphocytes (%)	0.982 (0.939-1.026)	0.408
Post-treatment NLR	0.975 (0.754-1.261)	0.847
Post-treatment PLR	1.001 (0.994-1.009)	0.760
Post-treatment MLR	1.000 (0.076-13.126)	1.000
ΔCD3+ T cell (%)	0.971 (0.928-1.017)	0.216
ΔCD4+ T cell (%)	1.817 (0.270-12.233)	0.540
ΔCD8+ T cell (%)	0.971 (0.946-0.998)	0.032	0.970 (0.934-0.998)	0.024
ΔNLR (%)	0.976 (0.584-1.629)	0.925
ΔPLR (%)	0.961 (0.320-2.888)	0.944
ΔMLR (%)	1.000 (0.991-1.009)	0.948
ΔCD3+ T cell (%)	0.960 (0.901-1.023)	0.205
ΔCD4+ T cell (%)	1.012 (0.959-1.069)	0.659
ΔCD8+ T cell (%)	0.906 (0.830-0.981)	0.016
ΔNLR	0.965 (0.760-1.225)	0.770
ΔPLR	0.999 (0.993-1.005)	0.842
ΔMLR	1.535 (0.302-7.801)	0.606

HR: Hazard ratio; CI: Confidence interval; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; MLR: Monocyte-to-lymphocyte ratio; ΔCD8+ T cells: Relative change in CD8+ T-cell proportion; PC: Poorly cohesive gastric adenocarcinoma.